Eye Meds Now

 Quick Ophthalmic Drug Search

231 items found
HYDROCORTISONE (hydrocortisone (1%) topical cream)
Over the Counter
Topical
Cream
Allergy Corticosteroids, Anti-inflammatory Corticosteroids
Indications/Usage:

Indicated for the temporary relief of itching associated with minor skin irritation and rashes due to eczema, insect bites, poison oak, poison sumac, soaps, detergents, cosmetics, jewelry, seborrheic dermatitis, or psoriasis scrapes.

This medication has a broad FDA approval for "minor skin irritation and rashes." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "minor skin irritation and rashes." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

Eyelid dermatitis (allergic, eczematous, or xeroderma):

  • Adults and childre≥ 2 years of age:
    • Apply externally to affected area not more than 3 – 4 times daily.
  • Children < 2 years of age:
    • Do not use, consult a doctor.

How Supplied:  
  • 1% topical cream:
    • 1 g tubes
    • 1.5 g tubes
    • 14.2 g tubes
    • 20 g tubes
    • 28 g tubes
    • 30 g tubes
    • 454 g tubes

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 59° – 86°F (15° – 30°C).
  • Avoid excessive heat and humidity.


IBUPROFEN (ibuprofen (200 mg; 400 mg; 600 mg; 800 mg) tablets; (200 mg) capsules; (100 mg) chewable tablets; (100 mg/5 mL) oral suspension)
Over the Counter
Oral
Capsules
Chewable Tablets
Oral Suspension
Tablets
NSAIDS
Indications/Usage:

Indicated for relief of mild to moderate pain.


Typical Dosing:  

►Mild to moderate pain:

  • 400 mg every 4 – 6 hours as necessary for relief of pain. In controlled analgesic clinical trials, doses of Ibuprofen tablets greater than 400 mg were no more effective than the 400 mg dose.
  • Carefully consider the potential benefits and risks of Ibuprofen tablets and other treatment options before deciding to use Ibuprofen tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals [See Warnings in package insert].
  • After observing the response to initial therapy, the dose and frequency should be adjusted to suit an individual patients' needs.
  • Do not exceed 3200 mg total daily dose.
  • If gastrointestinal complaints occur, administer with meals or milk.

How Supplied:  
  • Capsules:
    • 200 mg capsules
  • Tablets:
    • 200 mg tablets
    • 400 mg tablets
    • 600 mg tablets
    • 800 mg tablets
  • Chewable tablets:
    • 100 mg chewable tablets
  • Oral suspension:
    • 100 mg/5 mL (5 mL; 118 mL; 120 mL; 473 mL bottles)

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at room temperature.
  • Avoid excessive heat – 104°F (40°C).


ILEVRO (nepafenac (0.3%) ophthalmic suspension)
Prescription
Topical
Ophthalmic Suspension
NSAIDS
Indications/Usage:

Indicated for the treatment of pain and inflammation associated with cataract surgery.


Typical Dosing:  

►Pain and inflammation associated with cataract surgery, recommended:

  • 1 drop should be applied to the affected eye 1 time daily beginning 1 day prior to cataract surgery, continued on the day of surgery and through the first 2 weeks of the post-operative period. An additional drop should be administered 30 to 120 minutes prior to surgery.
  • Use with other topical ophthalmic medications:
    • May be administered in conjunction with other topical ophthalmic medications such as beta-blockers, carbonic anhydrase inhibitors, alpha-agonists, cycloplegics, and mydriatics.
    • If more than 1 topical ophthalmic medication is being used, the medicines must be administered at least 5 minutes apart.

How Supplied:  
  • 1.7 mL bottles
  • 3 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 36˚ – 77˚F (2˚ – 25˚C).
  • Protect from light.


Assistance: Payment Assistance

ILUVIEN (fluocinolone acetonide (0.19 mg) intravitreal implant )
Prescription
Injectable
Injectable Implant
Anti-inflammatory Corticosteroids
Indications/Usage:

Indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.


Typical Dosing:  

►Diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure, recommended:

  • For ophthalmic intravitreal injection.
  • ILUVIEN is a non-bioerodable intravitreal implant in a drug delivery system containing 0.19 mg fluocinolone acetonide, designed to release fluocinolone acetonide at an initial rate of 0.25 mcg/day and lasting 36 months.
  • Administration:
    • The intravitreal injection procedure should be carried out under aseptic conditions, which include use of sterile gloves, a sterile drape, a sterile caliper, and a sterile eyelid speculum (or equivalent).
    • Adequate anesthesia and a broad-spectrum microbicide should be given prior to the injection.
    • The injection procedure for ILUVIEN is as follows:
      • The exterior of the tray should not be considered sterile. An assistant (non-sterile) should remove the tray from the carton and examine the tray and lid for damage. If damaged, do not use unit. If acceptable, the assistant should peel the lid from the tray without touching the interior surface.
      • Visually check through the viewing window of the preloaded applicator to ensure that there is a drug implant inside.
      • Remove the applicator from the tray with sterile gloved hands touching only the sterile interior tray surface and applicator.
      • Prior to injection, the applicator tip must be kept above the horizontal plane to ensure that the implant is properly positioned within the applicator.
      • To reduce the amount of air administered with the implant, the administration procedure requires two steps. Before inserting the needle into the eye, remove the protective cap then gently push the applicator button down and slide it to the first stop (at the curved black marks alongside the button track). At the first stop, release the button and it should move to the UP position. If the button does not rise to the UP position, do not proceed with this unit.
      • Optimal placement of the implant is inferior to the optic disc and posterior to the equator of the eye. Measure 4 millimeters inferotemporal from the limbus with the aid of calipers for point of entry into the sclera. Sections or subsections omitted from the full prescribing information are not listed.
      • Inspect the tip of the needle to ensure it is not bent.
      • Gently displace the conjunctiva so that after withdrawing the needle, the conjunctival and scleral needle entry sites will not align. Care should be taken to avoid contact between the needle and the lid margin or lashes. Insert the needle through the conjunctiva and sclera. To release the implant, while the button is in the UP position, advance the button by sliding it forward to the end of the button track and remove the needle. Note: Ensure that the button reaches the end of the track before removing the needle.
      • Remove the lid speculum and perform indirect ophthalmoscopy to verify placement of the implant, adequate central retinal artery perfusion and absence of any other complications.
  • Following the injection, patients should be monitored for elevation in intraocular pressure and for endophthalmitis. Monitoring may consist of a check for perfusion of the optic nerve head immediately after the injection, tonometry within 30 minutes following the injection, and biomicroscopy between two and seven days following the injection. Patients should be instructed to report without delay any symptoms suggestive of endophthalmitis.

How Supplied:  
  • Sterile single use preloaded applicator supplied with 25 gauge needle

Preservatives:  

None listed in package insert.


Storage:  
  • Store between 59° – 86°F (15° – 30°C).


Assistance: Payment Assistance

INVELTYS (loteprednol etabonate (1%) ophthalmic suspension)
Prescription
Topical
Ophthalmic Suspension
Anti-inflammatory Corticosteroids
Indications/Usage:

Corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery.


Typical Dosing:  

►Post-operative inflammation and pain following ocular surgery:

  • Instill 1 – 2 drops into the affected eye twice daily beginning the day after surgery and continuing throughout the first 2 weeks of the post-operative period.
  • Administration instructions:
    • Instruct patient to wash hands well before each use.
    • Shake for 1 – 2 seconds before using.
    • If the patient is using other eye drops in addition to INVELTYS, advise the patient to wait at least 5 minutes between installation of INVELTYS and other eye drops.

How Supplied:  
  • 2.8 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store upright at 59° – 77°F (15° – 25°C).
  • Do not freeze.
  • Do not use if tamper-evident overcap seal is not intact.
  • The white tamper-evident overcap can be thrown away. Retain the pink cap and keep the bottle tightly closed when not in use.


Assistance: Payment Assistance

ISOPTO CARPINE (pilocarpine hydrochloride (1%, 2%, or 4%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Miotics
Indications/Usage:

Indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; management of acute angle-closure glaucoma; prevention of post-operative elevated IOP associated with laser surgery and induction of miosis.


Typical Dosing:  

►Elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension:

  • 1 drop (1%, 2%, or 4% solution) applied topically in the eye(s) up to 4 times daily. Pilocarpine-naïve patients should be started on the 1% concentration as higher concentrations are often not tolerated initially. The frequency of instillation and concentration of Isopto® Carpine are determined by the severity of the elevated IOP and miotic response of the patient.
  • To limit systemic exposure to pilocarpine, patients may be instructed to perform punctal occlusion for 2 minutes after instillation of Isopto® Carpine ophthalmic solution.

►Acute angle-closure glaucoma, initial management:

  • Prior to Isopto® Carpine use, treatment with secretory suppressants and hyperosmotic agents may be needed to lower IOP below 50 mmHg and relieve iris ischemia.
  • Apply 1 drop (1% or 2% solution) topically in the eye(s) up to 3 times over a 30-minute period.
  • If laser iridoplasty or iridomy is used to break the attack, 1 drop of Isopto® Carpine 4% should be administered prior to the procedure. Following laser iridoplasty, 1 drop of Isopto® Carpine 1% should be administered 4 times daily until an iridotomy can be performed.

►Post-operative elevated IOP associated with laser surgery, prevention:

  • 1 drop (1%, 2%, or 4% solution) (or 2 drops administered 5 minutes apart) should be applied topically in the eye(s) 15 – 60 minutes prior to surgery.

►Miosis, induction:

  • 1 drop  (1%, 2%, or 4% solution) (or 2 drops administered 5 minutes apart) should be applied topically in the eye(s).

►Use with other topical ophthalmic medications:

  • May be used in combination with beta-blockers, carbonic anhydrase inhibitors, sympathomimetics or hyperosmotic agents. If more than 1 topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.

►Use in pediatric patients:

  • In children < 2 years of age:
    • 1 drop of Isopto® Carpine 1% applied topically in the eye(s) 3 times daily.
  • Children ≥ 2 years of age should be dosed as for adults.
  • For the induction of miosis prior to goniotomy or trabeculotomy in children, 1 drop of Isopto® Carpine 1% or 2% should be applied topically in the eye 15 – 60 minutes prior to surgery.

How Supplied:  
  • 1% Ophthalmic solution:
    • 15 mL bottles
  • 2% Ophthalmic solution:
    • 15 mL bottles
  • 4% Ophthalmic solution:
    • 15 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 68° – 77°F (20° – 25°C).
  • Excursions permitted between 59° – 77°F (15° – 30°C).
  • Protect from freezing.


ISTALOL (timolol maleate (0.5%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Beta Blocking Agents
Indications/Usage:

Indicated in the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.


Typical Dosing:  

►Elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma: 

  • 1 drop in the affected eye(s) once a day in the AM.

How Supplied:  
  • 2.5 mL bottles
  • 5 mL bottles

Preservatives:  

benzalkonium chloride 


Storage:  
  • Store at 59° – 77°F (15° – 25°C).


Assistance: Payment Assistance

JETREA (ocriplasmin (1.25 mg/mL) intravitreal solution)
Prescription
Injectable
Intravitreal
Other Medications
Indications/Usage:

Indicated for the treatment of symptomatic vitreomacular adhesion.


Typical Dosing:  

Symptomatic vitreomacular adhesion:

  • 0.125 mg (0.1 mL of the solution) administered by intravitreal injection to the affected eye once as a single dose.
    • For single-use ophthalmic intravitreal injection only.
    • Must only be administered by a qualified physician.
    • This formulation of JETREA does not require dilution.
  • Additional information for Preparation for Administration and Administration and Monitoring is in Notes below.

How Supplied:  
  • 0.375 mg/0.3 mL single-use vials (0.3 mL each)

Preservatives:  

None listed in package insert.


Storage:  
  • Store frozen at or below -4°F (-20°C).
  • Protect the vials from light by storing in the original package until time of use.


Assistance: Payment Assistance

Special Purchasing Instructions: How to Purchase

KEFLEX (cephalexin monohydrate (250 mg; 500 mg; 750 mg) capsules)
Prescription
Oral
Capsules
Antibiotics
Indications/Usage:

Indicated for the treatment of skin and skin structure infections, such as presptal cellulitis, internal hordeolum, dacryocystitis, caused by susceptible isolates of the following Gram-positive bacteria: Staphylococcus aureus and Streptococcus pyogenes.

This medication has a broad FDA approval for "skin and skin structure infections." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "skin and skin structure infections." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

Skin and skin structure infections:

  • Adults and patients  15 years of age: 
    • The usual dose is 250 mg every 6 hours, but a dose of 500 mg every 12 hours may be administered. Treatment is administered for 7 – 14 days. For more severe infections larger doses may be needed, up to 4 grams daily in 2 – 4 equally divided doses.
  • Children (> 1 year of age):
    • Recommended total daily dose is 25 – 50 mg/kg given in equally divided doses for 7 – 14 days. In the treatment of β-hemolytic streptococcal infections, duration of at least 10 days is recommended. In severe infections, a total daily dose of 50 – 100 mg/kg may be administered in equally divided doses.
  • Dosage adjustment is required in patients with severe and end stage renal disease (ESRD) defined as CrCl < 30 mL/min. 
  • Additional information for Dosage and Administration is in Notes below.

How Supplied:  
  • 250 mg capsules
  • 500 mg capsules
  • 750 mg capsules

Note: Oral solution and tablets of cephalexin are also available. Refer to "Cephalexin" drug card for information on oral solution and tablets.


Preservatives:  

None listed in package insert.


Storage:  
  • Store at 77ºF (25ºC).
  • Excursions permitted to 59º –  86ºF (15º – 30ºC).
  • Store in a tight, light-resistant container.


KETOPROFEN (ketoprofen (25 mg; 50 mg; 75 mg) capsules)
Prescription
Oral
Capsules
NSAIDS
Indications/Usage:

Carefully consider the potential benefits and risks of ketoprofen capsules USP and other treatment options before deciding to use ketoprofen capsules USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (See WARNINGS in package insert).

Ketoprofen capsules USP are indicated for the management of pain.


Typical Dosing:  

Mild-to-moderate pain:

  • Usual dose is 25 – 50 mg every 6 – 8 hours as necessary.
  • A smaller dose should be utilized initially in small individuals, in debilitated or elderly patients, or in patients with renal or liver disease (See PRECAUTIONS in package insert).
  • A larger dose may be tried if the patient’s response to a previous dose was less than satisfactory, but doses above 75 mg have not been shown to give added analgesia.
  • Daily doses above 300 mg are not recommended because they have not been adequately studied. Because of its typical non-steroidal anti-inflammatory drug-side-effect profile, including as its principal adverse effect GI side-effects (See WARNINGS and ADVERSE REACTIONS in package insert), higher doses of ketoprofen capsules should be used with caution and patients receiving them observed carefully.

How Supplied:  
  • 25 mg capsules
  • 50 mg capsules
  • 75 mg capsules

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Keep tightly closed.
  • Store at 68° – 77°F (20° – 25°C).
  • Dispense in a tight, light-resistant container with a child-resistant closure (as required).


KETOROLAC (ketorolac tromethamine (0.5%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
NSAIDS
Indications/Usage:

Indicated for the temporary relief of ocular itching due to seasonal allergic conjunctivitis and for the treatment of post-operative inflammation in patients who have undergone cataract extraction.


Typical Dosing:  

 ►Ocular itching due to seasonal allergic conjunctivitis, recommended:

  • Instill 1 drop into the affected eye(s) 4 times a day.

 Post-operative inflammation after cataract surgery, recommended:

  • Instill 1 drop into the affected eye(s) 4 times daily, beginning 24 hours after cataract surgery and continuing through the first 2 weeks of the post-operative period.

►Use with other topical ophthalmic medications: ketorolac ophthalmic solution has been safely administered in conjunction with other ophthalmic medications such as antibiotics, alpha-agonists, beta blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics. Drops should be administered at least 5 minutes apart.


How Supplied:  
  • 3 mL bottles
  • 5 mL bottles
  • 10 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 59° – 77°F (15° – 25°C). 
  • Protect from light.


LACRISERT (hydroxypropyl cellulose (5 mg) ophthalmic insert)
Prescription
Topical
Ophthalmic Insert
Other Medications
Indications/Usage:

Indicated for patients with moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. Indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions.

Also indicated for patients with: exposure keratitis, decreased corneal sensitivity, and recurrent corneal erosions.


Typical Dosing:  

Moderate to severe dry eye syndromes:

  • 1 insert in each eye once daily is usually sufficient to relieve the symptoms associated with moderate to severe dry eye syndromes. Individual patients may require more flexibility in the use of LACRISERT; some patients may require twice daily use for optimal results.
  • Clinical experience with LACRISERT indicates that in some patients several weeks may be required before satisfactory improvement of symptoms is achieved.

►Recurrent corneal erosion:

  • 1 insert once daily in the affected eye.

Additional information for Dosage and Administration is in Notes below.

Recurrent corneal erosion typical dosing is based on professional judgment. This is our medical opinion and may not be true in all clinical circumstances.

How Supplied:  
  • 5 mg ophthalmic inserts

Preservatives:  

None listed in package insert.


Storage:  
  • Store below 86°F (30°C).


Assistance: Payment Assistance

LASTACAFT (alcaftadine (0.25%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Antihistamines and Mast Cell Stabilizer Combinations
Indications/Usage:

Indicated for the prevention of itching associated with allergic conjunctivitis.


Typical Dosing:  

Itching associated with allergic conjunctivitis:

  • Instill 1 drop into each eye once daily.
  • If more than 1 topical ophthalmic medicinal product is being used, each one should be administered at least 5 minutes apart.

How Supplied:  
  • 3 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 59° – 77°F (15° – 25°C).
  • After opening, LASTACAFT® can be used until the expiration date on the bottle.


Assistance: Payment Assistance

LATANOPROST (latanoprost (0.005%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Prostaglandin Analogs
Indications/Usage:

Indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.


Typical Dosing:  

►Elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, recommended.

  • Instill 1 drop in the affected eye(s) 1 time daily in the evening. If 1 dose is missed, treatment should continue with the next dose as normal.
  • The dosage should not exceed once daily; the combined use of 2 or more prostaglandins, or prostaglandin analogs including latanoprost ophthalmic solution is not recommended. It has been shown that administration of these prostaglandin drug products more than once daily may decrease the IOP lowering effect or cause paradoxical elevations in IOP.
  • Reduction of the IOP starts approximately 3 – 4 hours after administration and the maximum effect is reached after 8 – 12 hours.
  • May be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than 1 topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.
  • Contact lenses should be removed prior to the administration of latanoprost ophthalmic solution, and may be reinserted 15 minutes after administration.

How Supplied:  
  • 2.5 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Protect from light.
  • Store unopened bottle(s) under refrigeration at 36° – 46°F (2° – 8°C).
  • During shipment to the patient, the bottle may be maintained at temperatures up to 104°F (40°C) for a period not exceeding 8 days.
  • Once a bottle is opened for use, it may be stored at room temperature up to 77°F (25°C) for 6 weeks.


LATISSE (bimatoprost (0.03%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Other Medications
Indications/Usage:

Indicated to treat hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness.


Typical Dosing:  

Hypotrichosis of the eyelashes:

  • Ensure the face is clean, makeup and contact lenses are removed.
  • Once nightly, place 1 drop on the disposable sterile applicator supplied with the package and apply evenly along the skin of the upper eyelid margin at the base of the eyelashes. 
  • The upper lid margin in the area of lash growth should feel lightly moist without runoff. Blot any excess solution runoff outside the upper eyelid margin with a tissue or other absorbent cloth.
  • Dispose of the applicator after one use. Repeat for the opposite eyelid margin using a new sterile applicator.
  • Do not reuse applicators and do not use any other brush/applicator to apply LATISSE®.
  • Do not apply to the lower eyelash line [See Warnings and Precautions (5.3, 5.4 in package insert) and Patient Counseling Information (17) in package insert].
  • Additional applications of LATISSE® will not increase the growth of eyelashes.
  • Upon discontinuation of treatment, eyelash growth is expected to return to its pre-treatment level.

How Supplied:  
  • 3 mL bottles with 70 applicators
  • 5 mL bottles with 140 applicators

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 36° – 77°F (2° – 25°C).


Assistance: Payment Assistance

LEVAQUIN (levofloxacin (500 mg; 750 mg) tablets)
Prescription
Oral
Tablets
Antibiotics
Indications/Usage:

Indicated in adult patients for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus or Streptococcus pyogenes.

This medication has a broad FDA approval for "uncomplicated skin and skin structure infections." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "uncomplicated skin and skin structure infections." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

►Uncomplicated skin and skin structure infections:

  • Adults: (CrCl  50 mL/min):
    • 500 mg once every 24 hours for 7 – 10 days.
  • Dosage adjustment in adults with renal impairment:
    • Administer LEVAQUIN® with caution in the presence of renal insufficiency. Careful clinical observation and appropriate laboratory studies should be performed prior to and during therapy since elimination of levofloxacin may be reduced.
    • No adjustment is necessary for patients with a CrCl  50 mL/min.
    • In patients with impaired renal function (CrCl < 50 mL/min), adjustment of the dosage regimen is necessary to avoid the accumulation of levofloxacin due to decreased clearance [See Use in Specific Populations (8.6) in package insert].
  • Consult package insert for additional information.

How Supplied:  
  • Tablets:
    • 500 mg tablets
    • 750 mg tablets

Preservatives:  

None listed in package insert.


Storage:  
  • Store at 59° – 86°F (15° – 30°C) in well-closed containers.


LEVOCETIRIZINE (levocetirizine dihydrochloride (5 mg) tablets)
Over the Counter
Oral
Tablets
Antihistamines
Indications/Usage:

Used to temporarily relieve these symptoms due to hay fever or other respiratory allergies: runny nose; sneezing; itchy, watery eyes; itching of the nose or throat.


Typical Dosing:  

►Symptoms due to hay fever or other respiratory allergies:

  • Adults  65 years of age:
    • Ask a doctor.
  • Adults and children 12 – 64 years of age:
    • Take 1 tablet (5 mg) once daily in the evening.
    • Do not take more than 1 tablet (5 mg) in 24 hours.
    • ½ tablet (2.5 mg) once daily in the evening may be appropriate for less severe symptoms.
  • Children 6 – 11 years of age:
    • Take ½ tablet (2.5 mg) once daily in the evening.
    • Do not take more than ½ tablet (2.5 mg) in 24 hours.
  • Children < 6 years of age:
    • Do not use.
  • Individuals with kidney disease:
    • Do not use.

How Supplied:  
  • 5 mg tablets

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 68° – 77°F (20° –  25°C).


LEVOCETIRIZINE CHILDREN'S (levocetirizine dihydrochloride (2.5 mg/5 mL) oral solution)
Over the Counter
Oral
Oral Solution
Antihistamines
Indications/Usage:

Used to temporarily relieve these symptoms due to hay fever or other respiratory allergies: runny nose; sneezing; itchy, watery eyes; itching of the nose or throat.


Typical Dosing:  

►Symptoms due to hay fever or other respiratory allergies:

  • Adults  65 years of age:
    • Ask a doctor.
  • Adults and children 12 – 64 years of age:
    • Take 5 mL or 10 mL once daily in the evening depending upon severity of symptoms.
    • Do not take more than 10 mL in 24 hours.
  • Children 6 – 11 years of age:
    • Take 5 mL once daily in the evening.
    • Do not take more than 5 mL in 24 hours.
  • Children 2 – 5 years of age:
    • Take 2.5 mL once daily in the evening.
    • Do not take more than 2.5 mL in 24 hours.
  • Children < 2 years of age:
    • Do not use.
  • Individuals with kidney disease:
    • Do not use.

How Supplied:  
  • 2.5 mg/5 mL oral solution

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 68° – 77°F (20° –  25°C).


LEVOFLOXACIN (levofloxacin (250 mg; 500 mg; 750 mg) tablets; (25 mg/mL) oral solution)
Prescription
Oral
Oral Solution
Tablets
Antibiotics
Indications/Usage:

Indicated in adult patients for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus or Streptococcus pyogenes.

This medication has a broad FDA approval for "uncomplicated skin and skin structure infections." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "uncomplicated skin and skin structure infections." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

►Uncomplicated skin and skin structure infections:

  • Adults: (CrCl  50 mL/min):
    • 500 mg once every 24 hours for 7 – 10 days.
  • Dosage adjustment in adults with renal impairment:
    • Administer levofloxacin with caution in the presence of renal insufficiency. Careful clinical observation and appropriate laboratory studies should be performed prior to and during therapy since elimination of levofloxacin may be reduced.
    • No adjustment is necessary for patients with a CrCl  50 mL/min.
    • In patients with impaired renal function (CrCl < 50 mL/min), adjustment of the dosage regimen is necessary to avoid the accumulation of levofloxacin due to decreased clearance [See Use in Specific Populations (8.6) in package insert].
  • Consult package insert for additional information.

How Supplied:  
  • Tablets:
    • 250 mg tablets
    • 500 mg tablets
    • 750 mg tablets
  • Oral solution:
    • 25 mg/mL oral solution (100 mL, 200 mL, 480 mL bottles)

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Tablets should be stored at 59° – 86°F (15° – 30°C) in well-closed containers.
  • Oral solution should be stored at 77°F (25°C).
    • Excursions permitted to 59° – 86°F (15° – 30°C).


LORATADINE (loratadine (10 mg) capsules; (10 mg) tablets; (5 mg; 10 mg) tablets, orally disintegrating)
Over the Counter
Oral
Capsules
Oral Disintegrating Tablets
Tablets
Antihistamines
Indications/Usage:

Used for the temporary relief of the following symptoms due to hay fever or other upper respiratory allergies: runny nose; sneezing; itchy, watery eyes; itching of the nose or throat.


Typical Dosing:  

►Runny nose; sneezing; itchy watery eyes; itching of the nose or throat:

  • Adults and children 6 years of age:
    • Do not take more than 1 tablet or capsule in 24 hours.
    • 1 tablet or capsule daily.
  • Children < 6 years of age:
    • Ask a doctor.
  • Individuals who have liver or kidney disease:
    • Ask a doctor.

How Supplied:  
  • Capsules:
    • 10 mg capsules
  • Tablets:
    • 10 mg tablets
  • Tablets, orally disintegrating
    • 10 mg tablets, orally disintegrating

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 68° – 77°F (20° – 25°C).
  • Protect from excessive moisture.
  • Protect from freezing.
  • Use orally disintegrating tablets immediately after opening individual blister.


231 items found